Palatin Technologies, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.51) Per Share (NYSEAMERICAN:PTN)

Posted by Maddie Sorensen on Oct 5th, 2024

Palatin Technologies, Inc. (NYSEAMERICAN:PTN – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Palatin Technologies in a research note issued to investors on Tuesday, October 1st. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings of ($0.51) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. HC Wainwright also issued estimates for Palatin Technologies’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

Palatin Technologies Price Performance

Shares of PTN opened at $0.88 on Thursday. Palatin Technologies has a one year low of $0.68 and a one year high of $5.65. The firm has a market capitalization of $17.11 million, a P/E ratio of -0.36 and a beta of 1.01.

Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last announced its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Palatin Technologies

A hedge fund recently bought a new stake in Palatin Technologies stock. Armistice Capital LLC acquired a new position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,678,101 shares of the biopharmaceutical company’s stock, valued at approximately $3,272,000. Armistice Capital LLC owned approximately 8.66% of Palatin Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 11.50% of the company’s stock.

About Palatin Technologies

(Get Free Report)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.